Salute e Benessere

Casino Group: Release of the H1 2024 financial report

RELEASE OF THE HALF YEAR 2024FINANCIAL REPORT The Group has released its half year 2024 financial report, in English, on its website. It is available following this link: https://www.groupe-casino.fr/wp-content/uploads/2024/08/H1-2024-Financial-Report.pdfAnalyst and investor contactsChristopher Welton +33 (0)1 53 65 64 [email protected] Charlotte Izabel +33 (0)1 53 70 51 29 [email protected] Relations +33 (0)1...
Nasdaq GlobeNewswire
02/08/2024

The Department of Health - Abu Dhabi provides gene therapy for Duchenne Muscular…

While previously the therapy was accessible only inthe United States, this groundbreaking treatment will now also be offered atSheikh Khalifa Medical City (SKMC), part of SEHA; a subsidiary of PureHealth, further cementingAbu Dhabi'sposition as a leading healthcare destination and life sciences hub globally. The treatment was approved by the U.S. Food and Drug Administration (FDA) inJune 2023, and it was administered to an Emirati DMD patient by a specialist team led by a...
PR Newswire
02/08/2024

Pharmaceutical Contract Manufacturing Market worth $319.6 billion by 2029 driven…

Browse in-depth TOC on "Pharmaceutical Contract Manufacturing Market" Browse in-depth TOC on "Pharmaceutical Contract Manufacturing Market" 148 - Tables60 - Figures415 - Pages Thermo Fisher Scientific, Inc.: Market Leader in Pharmaceutical Contract Manufacturing Thermo Fisher Scientific, Inc. stands as a dominant force in the pharmaceutical contract manufacturing market, holding the largest market share in 2023. The company excels with a comprehensive suite of...
PR Newswire
02/08/2024

Facial Injectables Market Poised to Reach US$ 37.1 Billion by 2031, Driven by…

Penetration of Social Media Responsible for Bright Facial Injectables Market Outlook Penetration of Social Media Responsible for Bright Facial Injectables Market Outlook Facial injectables are commonly used on nasolabial folds, cheekbones, and lips. For instance, dynamic wrinkles caused by different movements are minimized by injecting botulinum toxin, often known as Botox, into the face's muscles. Rise in popularity of social media is a key factor fostering market expansion. A large...
PR Newswire
02/08/2024

Diabetes Supplements Market to Reach USD 13.4 billion by 2031, Growth at CAGR…

Research states that cinnamon, chromium, or berberine is likely of helping with controlling blood sugar. It further states that alpha-lipoic acid may also help in reduction of pain linked with diabetic neuropathy (nerve-related problems). Research states that cinnamon, chromium, or berberine is likely of helping with controlling blood sugar. It further states that alpha-lipoic acid may also help in reduction of pain linked with diabetic neuropathy (nerve-related problems). Request a PDF...
PR Newswire
02/08/2024

Unit dose packaging Market worth $43.8 billion by 2029 - Exclusive Report by…

Browse in-depth TOC on "Unit dose packaging Market". Browse in-depth TOC on "Unit dose packaging Market". 165 – Tables 53 – Figures 229– Pages Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=20819635 "Gel form segment to be the fourth largest growing form during the forecast period." Gel unit dose packaging accounts for roughly 10-15% of the market share. It is widely used in pharmaceuticals for topical gels and ointments, providing...
PR Newswire
02/08/2024

On-body Drug Delivery Devices Market to Reach US$ 796.1 Million Valuation by…

An on-body drug delivery device is a patched-on device delivering big molecules (biologics) subcutaneously and has been designed for therapies that periodically need a specific quantity of formulated drug. Typical applications comprise proteins such as monoclonal antibodies (mAbs). An on-body drug delivery device is a patched-on device delivering big molecules (biologics) subcutaneously and has been designed for therapies that periodically need a specific quantity of formulated drug. Typical...
PR Newswire
02/08/2024

Immunovia files US patent application to protect its next-generation test

Immunovia filed the provisional patent application with the Patent and Trademark Office (PTO) in the United States of America, the first market for commercializing the company's new test. In coming months, the company expects to submit additional clinical data to the USPTO bolster the patent application. Immunovia filed the provisional patent application with the Patent and Trademark Office (PTO) inthe United States of America, the first market for commercializing the company's new test...
PR Newswire
02/08/2024

EUROBIO SCIENTIFIC COMPLETES ACQUISITION OF ENDOPREDICT® GENOMIC TEST FROM…

EUROBIO SCIENTIFIC COMPLETES ACQUISITION OF ENDOPREDICT ®GENOMIC TEST FROM MYRIAD GENETICSParis, August 2 nd, 2024 –7:30 amEurobio Scientific(FR0013240934, ALERS), a leading French group inin vitrospecialty medical diagnostics and life sciences, announces the finalisation of its agreement with Myriad Genetics to acquire the EndoPredict® genomic test.As part of the agreement announced on 7 May 2024 (see press release below), on 1 August 2024 the Group has completed...
Nasdaq GlobeNewswire
02/08/2024

MTD Group completes the acquisition of Ypsomed's Pen Needles and Blood Glucose…

With this acquisition, MTD strengthens its position as the clear number two in the global pen needles market. This strategic acquisition not only solidifies our leadership in diabetes care but also underscores our commitment to delivering cutting-edge solutions for both self-care and professional use. We will integrate Ypsomed's pen needles operations into our European production and distribution network, bringing our total production capacity to over 2.5 billion pen needles. With this...
PR Newswire
02/08/2024

FDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL…

/refractory B-cell acute lymphoblastic leukemia (ALL).“We are excited that the FDA granted CLLS52 (alemtuzumab) ODD designation status. The importance of adding alemtuzumab to the lymphodepletion regimen has been demonstrated in Cellectis' BALLI-01 study, where the addition of this lymphodepletion agent to the fludarabine and cyclophosphamide regimen was associated with sustained lymphodepletion and significantly higher UCART22 cell expansion allowing for greater clinical activity,” said...
Nasdaq GlobeNewswire
01/08/2024

Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common…

Zymeworks intends to commence the Share Repurchase Program with $30.0 million in initial repurchases anticipated to begin promptly and continue during the second half of 2024 “Our decision to undertake a Share Repurchase Program reflects our confidence in the future outlook of our business, the strength of our pipeline, and our commitment to delivering value to our stockholders,” said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. “This strategic initiative allows us to...
Nasdaq GlobeNewswire
01/08/2024

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grants were made in reliance on the employment inducement exemption under the NYSE's Listed Company Manual Rule 303A.08.The Company is issuing this...
Nasdaq GlobeNewswire
01/08/2024

Galapagos reports half-year 2024 financial results and provides second quarter…

Executing on ourForward,Fasterstrategy with strong progress in a pivotal year, focused on delivering regulatory and clinical milestones, expanding our cell therapy manufacturing capabilities, and advancing our early-stage programs.Submitted IND application to FDA for our Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101 in R/R NHL.Submitted CTA to EMA for our Phase 2 study of GLPG5201 in R/R CLL with or without RT.IND filing for our Phase 1/2 EUPLAGIA-1 study of CD19...
Nasdaq GlobeNewswire
01/08/2024

Alvotech to Report Financial Results for the First Half of 2024 on August 15…

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, will release financial results for first half of the year ended June 30, 2024, after U.S. markets close on Thursday, August 15, 2024, and will conduct a conference call with analysts to present the financial results and recent business highlights on Friday August 16, 2024, at 8:00 am EDT (12 noon GMT). Live audio of the conference call will also be...
Nasdaq GlobeNewswire
01/08/2024

Performance Health Releases New Customer Commitment

"We are proud to enable the journey of independence and performance for clinicians and patients," said Tom Atkinson, UK General Manager. "This commitment to our customers is supported by three core strengths of our business. Each strength demonstrates the importance of our mission." "We are proud to enable the journey of independence and performance for clinicians and patients," saidTom Atkinson, UK General Manager. "This commitment to our customers is…
PR Newswire
01/08/2024

Transparency Notification from Shareholders

Transparency Notification from ShareholdersPRESS RELEASE REGULATED INFORMATION1 August 2024, 06:30 pm CESTGhent, Belgium – 1 August 2024 – Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification from the parties listed below, notifying the number of voting rights attached to the shares mentioned...
Nasdaq GlobeNewswire
01/08/2024

Phenomenex broadens its "Designed for PFAS" Portfolio with the expansion of the…

We launched the first stacked PFAS cartridge over seven years ago for our customers to expand on the ever-evolving nature of PFAS sample preparation. Recognizing that one size does not solve all challenges, our latest additions to the Strata PFAS portfolio include single and dual solid-phase extraction (SPE) phases, formats, and increased capacity. We believe these solutions will allow our customers to effectively address extraction, reproducibility, interference removal, clean-up, and efficient…
PR Newswire
01/08/2024

CARBIOS and SASA enter discussions for license of 100k ton/year PET biorecycling…

Clermont-Ferrand (France) and Adana (Turkey), Thursday 1 August 2024 (6pm CEST). CARBIOS,(Euronext Growth Paris : ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, andSASA, one of the world's leading manufacturers of polyester, fiber, filament yarn, polyester-based polymers, specialty polymers and intermediates, have signed a Letter of Intent (LOI) to cooperate through SASA's potential acquisition...
Nasdaq GlobeNewswire
01/08/2024

IBA - Regulated Information

(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings)Louvain-la-Neuve, Belgium, August 1st, 2024 06:00 Summary of the notificationIBA (Ion Beam Applications), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received...
Nasdaq GlobeNewswire
01/08/2024

RingConn Launches Gen 2 Smart Ring: Pioneering Sleep Apnea Detection with…

Revolutionizing Sleep Apnea Detection Revolutionizing Sleep Apnea Detection The RingConn Gen 2 addresses a critical health concern affecting millions worldwide. Approximately 936 million adults aged 30-69 years are estimated to have mild to severe sleep apnea. Of these, about 425 million adults have moderate to severe sleep apnea*, which lead to increased risk of hypertension, heart disease, and stroke. Conventional sleep apnea diagnosis PSG typically involves overnight stays in sleep...
PR Newswire
01/08/2024

Ultimovacs Announces Poster Presentation of NIPU Phase II Trial Update at…

Oslo, August 1, 2024:Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that an update from the Phase II NIPU trial (NCT04300244) in patients with malignant mesothelioma will be presented in a poster presentation at the 2024 ESMO Congress. The conference will be held in Barcelona, Spain from September 13-17, 2024.Poster Presentation Details:Title:Updated survival and vaccine response...
Nasdaq GlobeNewswire
01/08/2024

Remote Patient Monitoring Market to Hold Substantial Growth with a Striking…

The RPM systems deliver services with enhanced chronic disorders management comprising early detection of health signals along with a progress tracker, thereby impelling the RPM market. Also, the recent pandemic resulted in shortage of beds in hospitals, and patients suffering from chronic diseases were advised to stay at home due to the growing risk of getting infection. This ultimately propelled remote patient monitoring market. The RPM systems deliver services with enhanced chronic…
PR Newswire
01/08/2024

TraceLink and Tecsys Collaboration Brings Advanced Supply Chain Management to…

Integrated Solutions for Enhanced Supply Chain Management Integrated Solutions for Enhanced Supply Chain Management TraceLink and Tecsys bring together their respective strengths to offer health systems unparalleled visibility and control over their supply chains and inventory. The integration of TraceLink's multi-enterprise digital network platform with Tecsys' enterprise health warehouse management system enables health systems to: Tangible Benefits for Health Systems The...
PR Newswire
01/08/2024
Altri  Comunicati